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Abstract
The clonally variant Plasmodium falciparum PfEMP1 adhesin is a virulence factor and a prime target of humoral immunity. It
is encoded by a repertoire of functionally differentiated var genes, which display architectural diversity and allelic
polymorphism. Their serological relationship is key to understanding the evolutionary constraints on this gene family and
rational vaccine design. Here, we investigated the Palo Alto/VarO and IT4/R29 and 3D7/PF13_003 parasites lines. VarO and
R29 form rosettes with uninfected erythrocytes, a phenotype associated with severe malaria. They express an allelic Cys2/
group A NTS-DBL1a1 PfEMP1 domain implicated in rosetting, whose 3D7 ortholog is encoded by PF13_0003. Using these
three recombinant NTS-DBL1a1 domains, we elicited antibodies in mice that were used to develop monovariant cultures by
panning selection. The 3D7/PF13_0003 parasites formed rosettes, revealing a correlation between sequence identity and
virulence phenotype. The antibodies cross-reacted with the allelic domains in ELISA but only minimally with the Cys4/group
B/C PFL1955w NTS-DBL1a. By contrast, they were variant-specific in surface seroreactivity of the monovariant-infected red
cells by FACS analysis and in rosette-disruption assays. Thus, while ELISA can differentiate serogroups, surface reactivity
assays define the more restrictive serotypes. Irrespective of cumulated exposure to infection, antibodies acquired by
humans living in a malaria-endemic area also displayed a variant-specific surface reactivity. Although seroprevalence
exceeded 90% for each rosetting line, the kinetics of acquistion of surface-reactive antibodies differed in the younger age
groups. These data indicate that humans acquire an antibody repertoire to non-overlapping serotypes within a serogroup,
consistent with an antibody-driven diversification pressure at the population level. In addition, the data provide important
information for vaccine design, as production of a vaccine targeting rosetting PfEMP1 adhesins will require engineering to
induce variant-transcending responses or combining multiple serotypes to elicit a broad spectrum of immunity.
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Introduction
In sub-Saharan Africa, the main burden of Plasmodium falciparum
malarial disease affects children and adolescents, while older
subjects usually experience asymptomatic infections. This is
thought to reflect the gradual acquisition of immunity by
cumulated exposure to successive episodes of malaria caused by
diverse parasite strains [1] and antigenic variants [2,3]. A major
contributor to parasite diversity is the Plasmodium falciparum
erythrocyte membrane protein 1 (PfEMP1) variant adhesin that
the parasite inserts into the membrane of the erythrocyte in which
it develops. Surface expression of PfEMP1 bestows on the infected
red blood cell (iRBC) the capacity to cytoadhere to host cells [4], a
characteristic of this Plasmodium species and considered as an
important contributor to falciparum pathology. PfEMP1 is encoded
by a family of ,60 var genes, each of which codes for a protein
displaying specific binding and serologic characteristics. Successive
expression of distinct var genes by clonal antigenic variation is a
strategy used by the parasite to escape the host immune response
and to establish a persistent infection, thereby optimising
transmission.
PfEMP1 is a multi-modular adhesin, with an extracellular
binding region consisting of a variable number of different (five
types) Duffy-binding-like (DBL) and (three types) cysteine-rich
interdomain region (CIDR) adhesion domains, and a more
conserved cytoplasmic tail [5]. Diversity of PfEMP1 occurs both
within and between genomes. Within each genome, var paralogs
(with the exception of var3) differ in sequence, number of modules
and flanking regulatory sequences, and are classified into groups
A, B, and C, and B/A and B/C hybrid groups. Most var genes are
located in the unstable sub-telomeric regions of the chromosomes
and gene recombination during both meiosis and mitosis between
these paralogs is an important mechanism of repertoire diversi-
fication [6,7], even though recombination is constrained to occur
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structuring into groups is conserved but var repertoires differ in
their mosaic arrangement within individual modules, contributing
to extensive sequence (allelic) diversity of the domain orthologs.
Chimerism is particularly marked in var genes from group A (also
called UpsA), whose expression tends to be associated with severe
malaria and with infection in young children with a poorly
developed antibody response to the erythrocyte surface antigens
[10,11,12,13]. Whole genome comparison has shown that domain
arrangement and association differ in the various group A paralogs
from different repertoires, although individual domains have allelic
forms [14]. High sequence diversity has been observed in an
analysis of UpsA-associated DBLa tags from a global collection of
parasites [15].
Factors regulating variant antigen diversification remain unclear
but likely include a trade-off between diversifying antibody-driven
selection and purifying function-constrained selection. Longitudi-
nal follow-up studies indicate that malaria episodes tend to be
caused by parasites expressing iRBC surface variants correspond-
ing to gaps in the acquired antibody repertoire, suggesting
negative selection by pre-existing immune responses [3,16].
To gain insight into the immunological consequences of
chimerism and allelic polymorphism, we compared the antibody
response to a set of monovariant parasite lines that display an
allelic form of a PfEMP1 adhesion domain. We chose to study the
Palo Alto 89F5/VarO [17] and the IT4/R29 variant [18], which
both express orthologous NTS-DBL1a1 adhesion domains
mediating rosetting (i.e., binding uninfected red cells), a cytoad-
herence phenotype associated with severe malaria in African
children [19,20,21,22]. In addition, we identified PF13_0003 as
carrying an orthologous adhesion domain in the 3D7 genome [23]
and developed a monovariant 3D7/PF13 line that also formed
rosettes. Apart from the NTS-DBL1a1 domain, homology
between the downstream domains of the three PfEMP1 variants
is modest, allowing to explore the consequence of allelic
polymorphism of the adhesion domain associated with non-
orthologous domains.
We set out to analyse the serological relationships between the
three NTS-DBL1a1 adhesion domains, on one hand, and between
the iRBC surfaces of the three lines, on the other, to study how
allelic diversity impacts on antigenicity. We produced a soluble
recombinant NTS-DBL1a1 adhesion domain from each variant.
A prerequisite for the analysis of the iRBC surface serotype is the
use of monovariant cultures in which all parasites express the same
PfEMP1 variant. This had been achieved for VarO by positive
selection using variant-specific antibodies raised to the recombi-
nant NTS-DBL1a1 [17]. Using the same strategy, we have now
developed monovariant IT4/R29 and 3D7/PF13 parasite lines,
which both formed rosettes. Mouse antibodies elicited by each
recombinant NTS-DBL1a1 domain cross-reacted with their allelic
forms by ELISA but displayed strictly variant-specific iRBC
surface reactivity and variant-specific rosette disruption. Analysis
of naturally acquired antibodies from humans exposed to P.
falciparum living in Dielmo, Senegal, showed positively correlated
ELISA reactivities to the recombinant NTS-DBL1a1 domains.
Here also, however, reactivity with the iRBC surface was variant-
specific and the age-acquisition pattern differed for the three
variants. Absorption of sera with the recombinant domain showed
that the anti-NTS-DBL1a1 antibodies represented a large fraction
of the iRBC surface reactivity. Taken together, these data
demonstrate that the related rosette-forming parasites display
variant-specific iRBC-surface epitopes. Thus, PfEMP1 allelic
variation causes antigen diversification and participates in immune
evasion at the population level. In addition, these data provide
important information for vaccine development since a strategy
targeting rosetting will need either to combine multiple serotypes
or to engineer the antigen so as to broaden specificity.
Results
NTS-DBL1a1-VarO orthologs in the IT4 and 3D7 genome
In the 3D7 [23] and IT4 genomes [14] there are no var genes
with a similar gene architecture and a high sequence identity score
across the entire gene length, although the best identity scores for
individual domains were found in the subset of group A genes
[17]. Since the DBL1a1 domain mediates rosetting, we focussed
further work on genes harbouring the orthologous domain,
namely PF13_0003 (hereafter called PF13) and R29 (IT4var9)
(hereafter called R29) from in the 3D7 and IT4 genomes,
respectively. Both R29 and PF13 belong to the group A/UpsA var
genes with a typical PoLV Group 1 (2 cysteines/MFK*) sequence
signature [13,24]. Pairwise identity between the domains is close to
60% across the NTS-DBL1a1 protein sequence. The downstream
protein architecture of VarO, R29 and PF13 differs in the number
and type of DBL domains, and the presence of a second CIDR
domain in R29 and PF13 that is absent in VarO (Fig. 1). The
VarO domains downstream from the NTS-DBL1a1 have limited
homology with the downstream domains of R29 and PF13
(,30%), apart from the DBL2b and DBL5b domains of PF13
(38% identity) (Figure S1). Thus, VarO, R29 and PF13 display an
allelic form of the NTS-DBL1a1 domain combined with non-
allelic forms of partner domains.
Production of R29 and PF13 NTS-DBL1a1 recombinant
domains and mouse antisera
A recombinant, soluble NTS-DBL1a1 domain was produced in
E.coli for R29 and PF13 with a C-terminal His-tag. Protein purity
was checked by SDS-PAGE analysis under reducing and non-
reducing conditions and immunoblotting. The proteins migrated
at the expected molecular mass (Figure S2). N-terminal sequencing
identified a single sequence (data not shown), confirming protein
purity. Circular dichroism spectra in the near and far UV regions
indicated that the proteins were properly folded and N-terminal
sequencing of trypsinised fragments was consistent with the protein
being produced with the native conformation (data not shown), as
shown for the VarO domain [25].
The R29 and PF13 proteins elicited a consistent, homogeneous
and strong response, with high ELISA titres in outbred mice
(N=6 per antigen). The endpoint ELISA titre to the immunogen
was .6610
27 (Fig. 2), similar to the titre elicited by the VarO
recombinant domain [25].
Mouse anti-NTS-DBL1a1 antibodies cross-react in ELISA
with the allelic recombinant domains
Cross-reactivity of the various mouse sera was analysed on the
recombinant VarO, R29 and PF13 domains by ELISA and
compared to the reactivity with a domain from a paralog from a
distinct PoLV of DBL1a. We chose NTS-DBL1a PFL1955w,
encoded by an UpsB/C type paralog, with a Cys4, group 4
DBL1a domain and displaying 32–33% identity with the VarO,
R29 and PF13 domains (Figure S1). The recombinant PFL1955w
domain was produced using a similar strategy and its recognition
by the various antisera was studied in parallel with the other
proteins.
The anti-NTS-DBL1a1-VarO sera cross-reacted with the R29
and PF13 alleles, with 30- and 16-fold reduction of the 95% titre,
respectively; reaction with PFL1955w was quite modest as both
signal and titre were low (Figures 2A and S3). Importantly, this
Allele-Specific Red Cell Surface Malarial Antigens
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16544Figure 1. Domain organisation of the PfEMP1 proteins and sequence comparison of the NTS-DBL1a domains. (A) Schematic domain
organisation of the Palo Alto/varO, IT4/R29, 3D7/PF13_0003 and 3D7/PFL1955w PfEMP1 proteins. Regions corresponding to the recombinant NTS-
DBL1a domains are indicated by bars, with the N- and C-terminal residue numbers giving sequence limits. Domains in dark grey have .50%
sequence identity, shaded DBLb domains have ,38% identity; DBL1a-PFL1955w is shown in light grey (29–33% identity). (B) The NTS-DBL1a
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coli NTS-DBL1a1-VarO proteins (data not shown). Cross-
reactivity was not due to reaction with the His-tag present in the
VarO, R29 and PF13 recombinant proteins, as the sera failed to
react with e.g. the His-tagged CIDR-VarO construct (and vice
versa, data not shown). The anti-R29 sera cross-reacted with the
VarO and PF13 alleles with a 30- and 80-fold reduced 95% titre,
respectively, and reacted poorly with PFL1955w (Figure 2B). The
anti-PF13 sera cross-reacted more efficiently with VarO than with
R29 (16- and 45-fold reduction of the 95% titre, respectively)
(Figure 2C). They reacted with PFL1955w with a higher
maximum value than the antisera raised to VarO or R29,
although with low 50% and 95% titres.
Establishment of monovariant cultures of R29 and PF13
To investigate iRBC surface reactivity, we developed mono-
variant cultures of R29 and PF13, with .95% iRBC displaying
the PfEMP1 in question. Initially, the anti-NTS-DBL1a1-R29
polyclonal mouse antibodies reacted with less than 15% of the
trophozoite/schizont stages from a rosette-enriched IT4/R29
culture in which the rosetting phenotype had been maintained by
weekly enrichment (Figure 3A). This heterogeneity reflected
antigenic switching to other rosette-forming parasites that no
longer expressed R29. To enrich with parasites expressing R29,
we isolated the sub-population of anti-R29-positive iRBCs from
the rosette-enriched culture by cell sorting. This allowed to
establish an in vitro single variant culture of R29 in which a vast
majority of iRBC expressed the R29 protein.
To develop a single variant PF13 model, we hypothesised that
the PF13_0003 gene encoded a PfEMP1 mediating the formation
of rosettes, like its orthologs in the IT4 and Palo Alto lines. We
performed a weekly enrichment of rosette-forming parasites,
starting from a standard long-term 3D7 culture. After 10 weeks
of rosette-enrichment, a rosetting 3D7 culture was established. As
hypothesised, a fraction of these rosette-forming parasites tested
positive by flow cytometry for surface expression using the
polyclonal mouse anti-NTS-DBL1a1-PF13antibodies (Figure 3B).
Cell sorting from the multi-variant rosette preparation using the
polyclonal mouse sera selected the sub-population recognised by
the anti-NTS-DBL1a1-PF13 antibodies, allowing to establish a
monovariant PF13 culture, with 95% or more of the trophozoites/
schizonts staining positive and forming rosettes (Figure S4).
Further characterisation of the R29 and PF13 monovariant
cultures was carried out by RT-PCR, with mRNA extracted from
mature trophozoites. Analysis of the cDNA sequences obtained for
each culture perfectly matched the published sequence of R29 and
PF13, respectively, indicating that indeed, the R29- and PF13-
selected parasites expressed the corresponding PfEMP1 adhesin.
Subsequently, monoclonal antibodies (mAbs) were isolated from
animals immunised with the R29 or PF13 recombinant domain
and used bi-monthly for routine enrichment of R29-expressing
IT4 cultures or PF13-expressing 3D7 parasites following the
procedure described for VarO [17].
Absence of surface cross-reactivity of mouse sera raised
to the recombinant domains
The iRBC-surface reactivity of the various mouse anti-NTS-
DBL1a1 antibodies was analysed using the VarO, R29 and PF13
monovariant cultures. Although each antiserum reacted with its
cognate iRBC-surface, no cross-reactivity was observed with the
heterologous cultures expressing an allelic form of the NTS-
DBL1a1 domain (Figure 4A). This also held true when surface
reactivity of mAbs raised to the individual recombinant domain
was studied, as each reacted solely with the iRBC expressing the
cognate PfEMP1 from which the immunising NTS-DBL1a1 was
derived (Figure 4B). This allele-specific surface reactivity was
further emphasised when rosette disruption was studied
(Figure 4C). Each serum readily disrupted rosettes expressing the
sequences aligned as described in the Materials and Methods. Cysteine residues are shown in white on a black background and residues with 50% or
more sequence identity are shown in white on a grey background.
doi:10.1371/journal.pone.0016544.g001
Figure 2. ELISA titration curves of mouse sera against the NTS-
DBL1a recombinant domains. Serial two-fold dilutions of mouse
anti-VarO (A), anti-R29 (B), anti-PF13 (C) polyclonal sera (initial dilution
1/200) tested by ELISA against the recombinant domains. The plates
were coated with the VarO (squares), R29 (triangles), PF13 (open circles)
and PFL1955w (diamonds) domains; (x) indicates pre-immune sera.
doi:10.1371/journal.pone.0016544.g002
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allelic form. These results indicate that the various NTS-DBL1a1
domains elicited allele-specific surface-reacting antibodies in the
mouse.
Elevated seroprevalence of domain-reactive and iRBC
surface-reactive antibodies
The prevalence of antibodies to the various NTS-DBL1a1
recombinant domains was studied in a community living in a
malaria holoendemic area (Dielmo, Senegal). Serum samples of all
individuals (0.5 to 85 year old) were analysed. The threshold for
positive recognition was set from reactivity of non-immune French
adults. Seroprevalence to the R29 and PF13 recombinant domains
was very high, with 96.5% [95% confidence interval (CI) 94.07–
98.9] and 99.1% [97.9–100] positive sera, respectively, compared
to 87.7% [82.8–91.6] positive sera to VarO. As for VarO [17],
R29- and PF13-NTS-DBL1a1 seroconversion was observed in the
2–5 y age group (Figure 5A). Seroprevalence to the group B/C
PFL1955w domain was also quite high – at 95% [92.9–97.6] -
although the age distribution differed and was shifted towards
older children compared to the group A domains. The reactivities
to the three group A domains were highly correlated with each
other and moderately correlated to reactivity with PFL1955w
(Table 1).
Prevalence of surface-reactive IgG was also high, with 81.7%
[CI 76.4–86.9] and 87.1% [82.7–91.4] to the R29- and PF13-
iRBC surface, respectively, but slightly lower than the 93.9%
[89.7–96.4] previously observed for VarO with the same sera [17],
shown here for comparison (Figure 5B). The prevalence of VarO-
or PF13-surface-reactive antibodies rapidly increased with age,
with more than 80% of children having acquired surface-reactive
antibodies by the age of 5 y. The kinetics of acquisition for R29
was delayed by a few years, reaching its maximal value by the age
of 9–11 y. Surface reactivity to the three variants was positively
correlated. The correlation of iRBC surface reactivity with ELISA
reactivity to the cognate recombinant domain was modest and did
not differ from the correlation of reactivity with the allelic or
outsider domain (Table 1).
We next investigated whether naturally acquired antibodies to
VarO, R29, and PF13 iRBC cross-reacted with the iRBC surface
using the mixed agglutination assay [26]. For each rosetting
variant, iRBC were magnetically selected to obtain .95% iRBC
at mature stages and stained green or red with PKH57 or PKH26,
respectively, before being incubated with human sera. To validate
the assay, iRBCs of the same culture were differentially labelled
with the two dyes, mixed and incubated in the presence of sera
from non-immune individuals or from Dielmo villagers. No
agglutinates were detected with non-immune sera (data not
shown). VarO-, R29- or PF13-iRBC formed large mixed
agglutinates when incubated with malaria hyper-immune sera
(Figure 6). However, single-colour, variant-specific agglutinates
were formed when using mixtures of differentially stained VarO
and R29, VarO and PF13 or R29 and PF13 iRBC. Comparable
results were obtained with pooled sera and individual sera (data
not shown). Age of the serum donor did not influence serotype
specificity, as single colour agglutinates were observed with sera
from children as well as from adults.
This indicates that naturally acquired antibodies to the P.
falciparum variant surface are variant-specific. Reactivity with the
iRBC surface is the sum of binding to multiple variable epitopes
displayed by the various PfEMP1 domains and possibly by other
variant surface antigens. To evaluate the contribution of anti-
NTS-DBL1a1 antibodies to the overall iRBC surface-reactivity,
sera were depleted of NTS-DBL1a1-reactive antibodies by
immunoabsorption onto the recombinant antigen and tested for
iRBC surface reactivity, mixed agglutination and rosette disrup-
tion. The mean fluorescence intensity was markedly reduced after
depletion by NTS-DBL1a1 but was essentially unaffected by
absorption with an irrelevant recombinant protein (Figure 7). This
shows that anti-NTS-DBL1a1 antibodies constitute a large
fraction of surface-reactive antibodies.
Discussion
Allelic sequence diversity, chimerism and architectural diversity
of the var repertoire, together, pose formidable obstacles to the
study of immune responses acquired in endemic areas and to the
Figure 3. Isolation of monovariant cultures of IT4/R29 and 3D7/PF13_0003. Rosette-enriched IT4/R29 (A) and 3D7/PF13 (B) cultures were
incubated with polyclonal sera raised against recombinant domains and were isolated by cell sorting (see Materials and Methods). The left-hand
panels show surface positivity rates of the initial rosette-enriched cultures and the right-hand panels show the surface reactivity of the negative
(upper) and positive (lower) sorted populations. The x and y axes show Log10 fluorescence.
doi:10.1371/journal.pone.0016544.g003
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16544Figure 4. Variant-specific iRBC surface serotypes of Palo Alto/VarO, IT4/R29 and 3D7/PF13. (A) Surface immunofluorescence:
monovariant lines were incubated with mouse sera raised to the recombinant domain and analysed by FACS. Rows and columns show parasite lines
and sera, respectively, as indicated. The x and y axes show Log10 fluorescence. (B) Variant-specific surface reactivity of the mAbs raised to the
recombinant domains with the monovariant lines analysed by FACS. In each panel, the shaded area, the thick line and the thin line indicate reactivity
with Palo Alto/VarO, IT4/R29 and 3D7/PF13, respectively. (C) Variant-specific rosette disruption. Monovariant cultures were incubated with mouse
Allele-Specific Red Cell Surface Malarial Antigens
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Whether protective immunity is brought about by a broad
repertoire of antibodies against polymorphic PfEMP1 epitopes that
block reinfection, or by the slow acquisition of antibodies against
conserved PfEMP1 epitopes, is a critical issue for understanding the
evolutionary constraints on the var gene family and for designing
interventions targeting this family of adhesins. The presentwork has
aimed at obtaining insight into the immune responses mounted to
PfEMP1 adhesins displaying an allelic form of a rosette-mediating
adhesion domain, a cytoadherence phenotype commonly observed
in severe malaria. We were particularly interested to determine
whether naturally acquired antibodies to the surface-exposed
PfEMP1 molecule in the three parasite lines cross-reacted and
whether cross-reacting antibodies could be induced by immunising
mice with the shared adhesion domain.
Monovariant clonal lines expressing a single iRBC surface
serotype showed no evidence of antibody cross-reactivity of the
surface-exposed PfEMP1 epitopes even though ELISA cross-
reactivity to the natively folded recombinant domains was
observed. Human sera formed single colour agglutinates, irre-
spective of the donor age. These non-overlapping surface serotypes
indicate that allelic diversity and chimerism participate in strain
and serotype structuring. Although surface serotypes differed, clear
evidence of cross-reactivity with the recombinant NTS-DBL1a1
domains was observed in ELISA, suggesting that they belong to
the same serogroup. The data further show that immunisation
with the recombinant adhesion domain elicited variant-specific
surface-reacting antibodies, implying that vaccine development
will require either engineering an immunogen that induces
variant-transcending responses or combining multiple serotypes
serum as indicated and the fraction of mature stages forming rosettes was monitored. White, light grey and dark grey bars indicate Palo Alto/VarO,
IT4/R29 and 3D7/PF13, respectively.
doi:10.1371/journal.pone.0016544.g004
Figure 5. Seroprevalence for NTS-DBL1a domains and Palo Alto/VarO, IT4/R29 and 3D7/PF13 iRBC in Dielmo (Senegal).
Seroprevalence to recombinant domains (A) and the iRBC surface (B) in Dielmo, Senegal, measured by ELISA and FACS, respectively. The boundaries
of the boxes indicate the 25th and 75th percentiles, and the line in each box indicates the median. The whiskers indicate the 10th and 90th
percentiles. The outlying dots show values exceeding the 10th and 90th percentiles. The number of persons by age group was 9, 23, 19, 14, 12 and
158 in the 0.5-.2, 2-,5, 5-,7, 7-,9, 9-,11 and .11 years, respectively. Symbols used: open, VarO; light grey, R29; medium grey, PF13; dark grey,
PFL1955w (in A only).
doi:10.1371/journal.pone.0016544.g005
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variants.
The three var genes studied possess the structural signatures of
the small subgroup of group A/Cys2 type genes that has been
more particularly associated with severe disease [11,24] and/or
with disease in poorly immune, young children [13]. The large
allelic diversity of group A/Cys2 type var genes in the field
[13,15,24] supports the view that they are under immune
selection. The data presented here are consistent with this.
Antibodies naturally acquired by the Senegalese villagers failed to
cross-react with the iRBC surface of the heterologous rosette-
forming variants irrespective of the combination used. A lack of
surface serotype overlap was observed in all age groups, indicating
that cumulative exposure results in accumulating distinct antibody
specificities rather than developing broadly cross-reacting anti-
bodies. The age-association of antibody distribution in the
community and importantly, the non-overlapping surface sero-
types, support the conclusion that allelic diversity is an immune
escape and that antibodies participate in antigen diversification by
selecting variant sequences and by structuring strains into separate
serotypes. Nevertheless, we propose that serotypes include highly
related sequences, as it is unlikely that parasites displaying the
exact VarO, R29 or PF13_0003 sequences circulate in the village.
In the absence of information on the local var repertoire, which we
suppose is very large in view of the global diversity in Dielmo [27],
we suggest that the observed antibody responses were elicited by
parasites expressing genes presenting higher sequence identity
than the three allelic domains studied here (i.e., .60% identity).
The degree of homology needed to generate cross-reactive surface-
reacting antibodies is unknown. One study in India reported the
frequent occurrence of mixed-colour agglutinates with P. falciparum
isolate pairs tested with convalescent-phase sera [28]. It is unclear
why this was not observed in our study and in many studies with
parasites and sera from other endemic areas [29,30]. It is possible
that mixed agglutination assays lack sufficient sensitivity to detect
cross-reactive antibodies if these represent only a small fraction of
the surface-reactive antibodies. However, even in the case of
var2csa, which displays a limited population polymorphism [15,31],
surface serotypes do not fully overlap, as many human immune
sera form single-colour, isolate-specific agglutinates with CSA-
binding lines, with mixed agglutinates being infrequent and pan-
agglutination quite rare [29,31,32]. Similarly, human mAbs
reacting with PfEMP1-var2csa expressed by CSA-binding parasites
seem to target determinants not present in all lines [33]. However,
some antibodies elicited by var2csa or var1csa recombinant domains
cross-reacted with the surface of heterologous lines
[34,35,36,37,38,39]. By contrast, neither the mouse antisera nor
the mouse mAbs raised to the three recombinant rosetting
domains cross-reacted with the heterologous iRBC surface and
none were able to cross-disrupt rosettes. As the NTS-DBL1a1 is
the most conserved domain between the three variants, the
variant-specific surface reactivity could potentially be targeting the
more distant PfEMP1 domains downstream or other variant
surface antigens such as rifins or stevors. We can reasonably
exclude this possibility, however, since the marked reduction of
surface reactivity following absorption by the recombinant domain
showed that antibodies to NTS-DBL1a1 accounted for a large
fraction of surface seroreactivity.
Mapping the polymorphic residues onto the recently deter-
mined crystal structure of NTS-DBL1a1-VarO (Juillerat et al,
submitted) (Figure 8) revealed numerous surface-exposed poly-
morphic residues. These represent potential allelic variants of
surface-displayed epitopes and most likely account for much of the
specific surface seroreactivity of the human antibodies as well as of
antibodies induced by the recombinant domain (including mAbs).
Interestingly, however, the protein surface displays relatively
conserved areas as well, which may be candidates for binding
sites to heparin, which disrupts rosettes for all three variants
[17,40] (results not shown for PF13).
Another important lesson of the present work is that the analysis
of ELISA-reactive and surface-reactive antibodies reveals different
aspects of the antibody response. Indeed, although no surface
cross-reactivity could be observed, there was clear evidence of
cross-reactivity between the recombinant NTS-DBL1a1 domains
in ELISA, with higher titres and values on the allelic forms than on
the unrelated group C NTS-DBL1a. It appears that the group A/
Cys2 DBL1a1 antigens studied here form a group of related
serotypes, although more work is needed with additional domains
from other subgroups to substantiate this conclusion. Accordingly,
ELISA could potentially be used to define serogroups of related
orthologs/alleles or paralogs. Similar ELISA cross-reactivity was
reported with mouse or rabbit sera obtained by immunisation with
recombinant domains from var2csa [34,35,38,39] and from other
rosette-forming parasites [41]. The strong inter-domain correla-
tion and the similar age pattern of antibody acquisition observed
here for the three group A NTS-DBL1a1 domains in the
Senegalese community suggest that ELISA cross-reactivity occurs
with human sera as well, although this was not formally tested by
competition ELISA. Interestingly, limited intra-genome cross-
reactivity of human antibodies with a panel of DBL1a and CIDR
domains encoded by the 3D7 repertoire has been observed by
competition ELISA but this was restricted to a few domains that
shared more than 50% sequence identity [42]. This restricted
inter-paralog cross-reactivity contrasts with the inter-allelic
ELISA cross-reactivity observed here, and supports the interpre-
tation that the three alleles studied form a serogroup of related
serotypes. We suggest that ELISA detects more epitopes than
surface immunofluorescence, agglutination or rosette disruption
assays, perhaps by revealing conserved or shared epitopes of the
protein that are not surface-accessible but become unveiled when
coated on ELISA plates. In line with this, immunoblots of
monovariant cultures showed variant specificity under non-
reducing conditions but showed cross-reactivity under reducing
Table 1. Pairwise correlation of antibody reactivity to
individual recombinant domains with reactivity to iRBC
surface.
recombinant NTS-DBL1a iRBC surface
VarO R29 PF13 PFL1955 VarO R29 PF13
recombinant NTS-DBL1a
VarO 1
R29 .818
# 1
PF13 .784
# .815
# 1
PFL1955 .462
# .576
# .585
# 1
surface IFA
VarO .476
# .574
# 612
# .462
# 1
R29 .520
# .611
# .663
# .512
# .632
# 1
PF13 .515
# .506
# .642
# .418
# .651
# .627
# 1
#P,0.00001.
Pairwise comparisons are based on individual OD values determined by ELISA
and mean fluorescence intensity determined by FACS (all age groups).
Spearman correlation tests using STATA 9.2.
doi:10.1371/journal.pone.0016544.t001
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conserved epitopes have been detected in sera from individuals
living in areas where malaria is endemic [43,44]. This probably
accounts for the observation that ELISA reactivity with the
recombinant domain correlated only moderately with iRBC
surface reactivity. ELISA could thus be used to define serological
subgroups of related orthologs/alleles or paralogs, but it does not
predict surface reactivity and as such does not inform about
potential selective forces driving surface polymorphism in the
population. To study such selective forces - be they immunolog-
ical or functional/adhesive - work with isolates from patients and
with laboratory isolates should use monovariant, pure serotypes
and adhesion types. Generating a panel of such variants will
require a major community effort to derive the appropriate
reagents.
The VarO, R29 and PF13 surface serotypes were quite frequent
in the Senegalese community. They were acquired with different
kinetics, the earliest response being apparently to VarO.
Antibodies to R29 appear to be acquired later than antibodies
to VarO or PF13. The low seroprevalence in young children is
consistent with findings in Kenyan children [25]. Antibody
acquisition in young children is consistent with a role for rosetting
parasites in falciparum pathology, although children from Dielmo
are usually protected against severe malaria from a very young age
- earlier than the mean age for acquisition of surface-reacting
antibodies, including antibodies to VarO. While a different study
design is needed to analyse the potential contribution of the three
variants to severe malaria, we can conclude that acquisition of
specific antibodies coincides with mounting protecting response
against malaria disease. Although, the precise mechanism of this
Figure 6. Mixed agglutination assay with Palo Alto/VarO, IT4/R29 and 3D7/PF13 monovariant lines. After rosette disruption with
dextran sulphate, the RBC membrane was labelled with either PKH26 or PKH67, mixed in homologous or heterologous pairwise association, and
incubated with human serum in the presence of dextran sulphate. Agglutination was examined using a fluorescence microscope. A representative
example with an individual serum is shown. (A), (B) and (C) show mixed agglutinates of homologous PKH26- and PKH67-labeled Palo Alto/VarO, IT4/
R29 and 3D7/PF13 associations, respectively, while (D) shows a typical absence of mixed agglutinates using heterologous association (shown is a
PKH26-labeled Palo Alto/VarO and PKH67-labeled IT4/R29 association).
doi:10.1371/journal.pone.0016544.g006
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immunity against clinical malaria being brought about by the
acquisition of a large repertoire of antibodies preventing expansion
of a large number of antigenic variants.
We studied the domain-specific response using recombinant
NTS-DBL1a1 domains that are correctly folded, as they met not
only different biophysical criteria [25] but also induced surface
reactive, rosette-disrupting antibodies and bound RBC [17,40].
Figure 7. Residual VarO-iRBC surface reactivity after serum depletion of human sera using the recombinant VarO domain. FACS
analysis of serum from adults (A and C) and from a 6 y old child (B) living in Dielmo, Senegal before and after antibody depletion. The grey area
indicates fluorescence intensity distribution of non-immune French blood donors. The thick, dotted and thin lines indicate IFA distribution of non-
depleted, control TALON-absorbed, recombinant VarO-depleted serum, respectively. The x axis shows Log10 fluorescence.
doi:10.1371/journal.pone.0016544.g007
Figure 8. Sequence polymorphism of the three alleles mapped upon the NTS-DBL1a1 varO crystal structure. Three mutually
orthogonal views of the surface of the NTS-DBL1a1-varO crystal structure with sequence polymorphism between the three alleles, VarO, R29 and
PF13, colour-coded from blue (variable) to red (conserved - see the nine-point colour scale, insert). (A) and (C) are viewed with the C-terminus of the
domain at the bottom and are rotated with respect to each other by 180u about a vertical axis. (B) is a perpendicular view, seen from above (A) and
(C).
doi:10.1371/journal.pone.0016544.g008
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monitored using large panels of recombinant domains, although
their native folding was usually not assessed and domain
boundaries possibly not optimally designed. The definition of
individual domains is not straightforward, as the original
boundaries based on sequence alignment do not fully match with
the crystal structures. In particular, our structural analysis of NTS-
DBL1a1-varO.indicates that the NTS region is an intrinsic part of
the domain. The recombinant DBL1a domains used by other
groups to assess the acquired antibody response lacked the NTS
moiety and in some instances did not include a critical last pair of
cysteine residues [42,45,46,47,48]. It is therefore difficult to
compare published seroprevalence for group A-derived domains
with our findings. However, we note that the selevated
seroprevalence against NTS-DBL1a1-R29 in Dielmo is in line
with seroprevalence against DBL1a1-R29 in areas of high
endemicity [49].
Of note, sequence identity of PF13 with VarO and R29
predicted the cytoadherence phenotype, as the three lines indeed
formed dextran sulfate- and heparin-sensitive rosettes, suggesting
that orthologs of NTS-DBL1a1-VarO in other parasite genomes
are involved in rosetting as well. Our data also illustrate antigenic
switching occurring in the IT4/R29 line, since after several
months of culture including weekly enrichment for rosettes,
surface reactivity to NTS-DBL1a1-R29 had dropped below
20%. This reflects switching expression from the dominant
R29/IT4var9 gene to another rosette-mediating paralog. Rosetting
is encoded by a subset of var paralogs whose exact number is
unknown. To circumvent the consequences of antigenic switching
within the rosetting population in each of the three lines, we
developed specific mAbs to pan the culture at regular intervals.
Surface seroreactivity to patient isolates has been extensively
used to analyse the acquisition of responses [3,16,50,51,52,53,54],
but these studies did not permit definition of specific serotype/
serogroups as unpanned laboratory lines and patient isolates
express multiple var genes [11,55,56,57]. The same limitation
applies to analysis of serotypes using lines selected for a specific
cytoadherence because of the redundancy of cytoadherence
specificities in the var repertoire [14,58]. The only exception is
var2csa, since it is single copy in most lines and the only gene
associated with adhesion to CSA [59]; monovariant lines can be
thus readily selected by panning on CSA. Apart from var2csa-
expressing parasites, serology studies using monovariant lines are
scarce. Analysis of seroreactivity of Kenyan sera to the
monovariant A4u line panned using a specific mAb showed an
age- and transmission-dependent acquisition of surface seroreac-
tivity [47]. Interestingly, surface reactivity correlated poorly with
ELISA reactivity to individual recombinant domains derived from
the A4var gene expressed, consistent with our findings with the
rosette-forming lines.
Both naturally acquired antibodies and mouse antibodies to the
recombinant domains failed to show overlapping surface serotypes
between the three related group A/Cys2 variants studied. This has
major implications for vaccine development, as it indicates that
specific strategies should be developed in order to target this
particular subgroup considered serologically more conserved and
cross-reactive than variants expressed in older children [42,54]
and thus of major interest for the development of a vaccine against
severe falciparum malaria [13]. Such strategies could include the
combining of multiple serotypes or engineering the immunogen to
induce a broad reactivity. Both approaches face the challenge that
we need a deeper understanding of the number of distinct genes
implicated in rosetting and of their serogroup and serotype
diversity. Mapping of the surface epitopes and the surface areas
involved in adhesion will be facilitated by the recently determined
crystal structure of the VarO adhesion domain; the available
rosetting inhibitory anti-VarO mAbs should help this endeavour.
Materials and Methods
Production of NTS-DBL1a1 domains
Production of the VarO soluble recombinant domain has been
described [25]. Recodoned R29 (Gencust, amino acids 1–481) and
PF13 (GenScript; amino acids 1–486) domains had predicted N-
glycosylation sites mutated to NxA to allow possible expression in
eukaryotic systems and a C-terminal hexa-His tag. The coding
sequence was cloned in pET21a (Novagen), and transformed into
E. coli Rosetta-gami
TM 2 (DE3) (Novagen). Protein expression was
induced with 0.1 mM isopropyl-b-D-thio-galactopyranoside for
4 h at 30uC followed by 16 h at 20uC. Cells were resuspended in
20 mM Tris-HCl, 200 mM NaCl, pH 8 in presence of PMSF
(Fluka) and Protease inhibitor cocktail complete EDTA-free
(Roche) and lysed mechanically (EmulsiFlex-C5, Avestin). Soluble
proteins were purified by metal affinity (TALON, Clontech)
followed by size exclusion chromatography (Hiload 16/60 Super-
dex 200, GE Healthcare). The recodoned PFL1955w domain
(without mutations or His tag) was cloned in pMAL-c2X (New
England BioLabs) and expressed in E. coli SHuffle
TM Express
(New England BioLabs) as an MBP-fusion protein [25]. The
protein was purified on an amylose column equilibrated with
20 mM Tris/HCl, pH 8, 200 mM NaCl, and released by passing
the same buffer with 500 mM NaCl, 10 mM maltose. After size
exclusion chromatography in the same Tris buffer, the fusion
protein was cleaved with Factor Xa (Novagen) as described for the
VarO domain. The domain was separated from MBP on a PD-10
column (GE Healthcare) in 20 mM Tris/HCl, pH 8, 50 mM
NaCl, and a heparin column (HiTrap
TM heparin HP, GE
Healthcare) equilibrated with the same buffer. The domain was
eluted with 20 mM Tris/HCl, pH 8, 300 mM NaCl.
Production of mouse anti-NTS-DBL1a1 antibodies
Outbred mice were immunised as described [17]. Sera (N=6
per group) were collected prior to the first injection (pre-immune
sera) and 10 days after the third injection and stored at –20uC until
use. R29-specific mouse mAbs were custom-produced (Genscript).
PF13-specific mAbs were produced in-house as described [17].
MAbs were screened by ELISA on the immunising antigen and by
iRBC surface reactivity. Animal studies complied with institutional
guidelines of Institut Pasteur.
Monovariant cultures
P. falciparum parasites were cultured in human O
+ erythrocytes
[17]. Late trophozoites/young schizont stages of IT4/R29 were
weekly enriched for rosette-forming parasites by centrifugation on
ice-cold Ficoll (density 1.077 mg.mL
21, Abcys). For 3D7 (obtained
from MR4), weekly rosette enrichment for 2.5 months yielded a
rosette-forming parasite culture. After rosette dissociation with
10 mg.mL
21 dextran sulfate (Sigma) incubated for 30 min at 37uC,
mature iRBC were magnetically selected on a CS column (MACS,
Miltenyi Biotec). For cell sorting, the iRBC pellet was resuspended
in PBS, 2% foetal calf serum (FCS) and stained with anti-R29 or -
PF13 sera (final dilution 1/200), and a goat anti-mouse IgG Alexa
fluor 488 conjugate (dilution 1/1000). Surface-positive iRBCs
were sorted by flow cytometry (MoFlo flow cytometer, Dako) and
sub-cultured in O
+ erythrocytes. Rosette formation was then
selected by weekly enrichment and bi-monthly panning with
specific mAbs as described [17]. Rosetting frequency and surface
positivity in each monovariant culture was .90%.
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Serum samples from 235 villagers (.5–85 years old) living in
Dielmo (Senegal) were used. [17]. Non-immune sera from healthy
adults living in France (Blood Bank, EFS, Rungis) were used as
negative control.
ELISA, surface immunofluorescence and rosette
disruption assays
Experimental conditions for ELISA, surface immunofluores-
cence, flow cytometry and rosette-disruption assay using mono-
variant parasite cultures were as described [17].
Mixed agglutination assays
After rosette disruption using dextran sulfate, iRBC were
magnetically enriched. The iRBC membrane was labelled using
PKH67 or PKH26 (Invitrogen) following the manufacturer’s
instructions, followed by three washes with PBS-2% FCS. Cells
were resuspended in complete culture medium, 10 mg.mL
21
dextran sulfate. An equal volume of differentially stained iRBC
was mixed and incubated 1 h at 37uC with human sera (final
dilution 1/20) and Hoechst dye (dilution 1/1000). Immune
agglutinates were visualised using fluorescent microscopy (Leica).
An iRBC agglutinate was defined as a clump containing more
than three iRBC. Each serum was tested in duplicate in two
independent experiments.
Depletion of human sera on recombinant NTS-DBL1a1
protein
10 mg of the VarO protein was absorbed on 10 mL of TALON
resin (Clontech) for 1 h at 4uC. Unbound protein was removed by
three washes with 20 mM Tris/HCl, pH 8, 200 mM NaCl. The
resin was then incubated for 1 h at 4uC with human serum
samples (4 mL of serum, 1/10 final dilution). The depleted sera
were collected by centrifugation. Depletion was verified by ELISA.
Mapping of surface-exposed polymorphic residues
The CONSURF web server [60] was used to assign a colour
code according to the degree of conservation for each residue of
the three variant sequences, which were aligned by ClustalW and
corrected by hand, taking into account secondary structure
elements of NTS-DBL1a1-varO. The result was displayed using
PyMOL [61].
Statistical analysis
ELISA OD and surface IFA values were log-transformed. The
Student’s t-test and Wilcoxon’s nonparametric test were used to
compare normal and non normal distributions of log-transformed
data. Surface-reactive and domain-reactive antibodies were
correlated using Spearman rank correlation test. Data were
analyzed with STATA software (version 9.2, STATA corporation,
College Station, TX, USA) and P,0.05 was considered to be
statistically significant.
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This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Institut Pasteur (http://webcampus.
pasteur.fr/jcms/c_98517/protocoles-usuels) and complied with
the European Union guidelines for the handling of laboratory
animals (http://ec.europa.eu/environment/chemicals/lab_animals/
home_en.htm). The procedures were approved by the Institut
Pasteur animal care and use committee. Animal care and
handling was approved by the Ministe `re de l’Agriculture et de
la Pe ˆche (rapport 107503056792, clearance number 75–273,
issued on 28th August 2007 to OMP) and the protocols and
procedures used by the Direction de ´partementale des services
ve ´te ´rinaires de Paris (Ref. RL- 07031395-30701147) isued on
29th August 2007 to OMP.
The human study was conducted in accordance with the
Declaration of Helsinki and was approved by the Institutional
Review Board of the Institut Pasteur of Paris (reference: RBm/
2006.032 in September 2007) and by the National Council on
Health Research of Senegal (reference nu 05 MSP/DS/CNRS in
February 2008). Both review boards approved the verbal consent
procedures. The project objectives were carefully explained to
the assembled village population and the village head, the
spokesperson for the women, for the younger generation, the
religious authority of the village gave their informed consent.
Individual verbal informed consent was then obtained, as most
participants were illiterate, at each stage of the study. In formed
consent was obtained individually from all participants (parents
or ward of children) and was recorted in the individual villager’s
file. The possibility to withdraw from the project at any time was
stated.
Supporting Information
Figure S1 PfEMP1 protein sequence analysis. Pairwise
amino acid sequence identity between domains of similar subtype
from the Palo Alto/varO, IT4/R29, 3D7/PF13_0003 and 3D7/
PFL1955w PfEMP1 proteins.
(PDF)
Figure S2 SDS-Page analysis of the recombinant do-
mains. The recombinant NTS-DBL1a domains of VarO (lanes
1, 2), R29 (lanes 3, 4), PF13_0003 (lanes 5, 6) and PFL1955w (7,8)
were migrated under reducing (even lanes) or non-reducing (odd
lanes) conditions.
(PDF)
Figure S3 Cross-reactivity between allelic domains
measured by ELISA. ELISA 50% and 95% titres of sera from
mice immunised with individual recombinant NTS-DBL1a1
domains tested against the recombinant domains (top chart).
Reduction factor of reactivity with the heterologous domains
(bottom chart).
(PDF)
Figure S4 Rosette-forming, surface-positive sorted
iRBC used to derive IT4/R29 and 3D7/PF13_monovar-
iant lines. Microscopic visualisation (left) and immunostaining
(right) of rosettes from the IT4/R29 (A) and 3D7/PF13_0003 (B)
monovariant cultures obtained after cell sorting with mouse sera
raised to the recombinant R29 and PF13_0003 domains
respectively.
(PDF)
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